title: [Interferons alpha in the treatment of chronic HCV infections].
abstract: Interferons play the main role in the treatment of chronic hepatitis C. In the clinical practice recombined forms of these cytokines dominate. Most recent obligatory standard of the treatment is combined therapy with pegylated interferon and ribavirin during 24 or 48 weeks dependent of HCV genotype. In some clinical cases, in which contraindications to these forms of drugs or adverse events appear, administration of natural interferon (alphaferon) is possible. Treatment with this form of interferon in these cases is safe and efficient.
authors.affiliation: Katedra i Klinika Chorób Zakaźnych Akademii Medycznej im. L.Rydygiera w Bydgoszczy. kikchzak@amb.bydgoszcz.pl
authors.forename: Waldemar
authors.initials: W
authors.lastname: Halota
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Pawłowska
authors.forename: Michaił
authors.initials: M
authors.lastname: Andrejczyn
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a